News Coverage
- 2020
-
October 15, 2020 October 15, 2020 Episode 67: Succeeding Through Adversity
Learn MoreOctober 12, 2020 The new dealmaking normal, will it continue post-pandemic?
Learn MoreAugust 24, 2020 Targeted Oncology: Promising Phase 3 Study of CPI-613 in Metastatic Pancreatic Cancer Achieves Target Enrollment Early
Learn MoreJuly 27, 2020 ROI-NJ: Some Local Firms Hope to Bring Bigger Portion of Pharma Manufacturing Back to U.S. — and N.J.
Learn MoreJune 22, 2020 OncLive: Dr. Alistar on the Need to Develop Biomarkers in Pancreatic Cancer
Learn MoreJune 9, 2020 OncLive: Philip Highlights Promise of Devimistat in Pancreatic Cancer
Learn MoreMay 25, 2020 The Jerusalem Post: Despite COVID-19, Pivotal Pancreatic Cancer Study in Israel Hits Benchmark
Learn MoreApril 30, 2020 RARECast: Targeting the Metabolism of Rare Cancers
Learn MoreApril 28, 2020 Clinical Leader: COVID-19 Presents Unique Challenges For Oncology Trials
Learn MoreApril 8, 2020 Empowered Patient Podcast: Developing Cancer Metabolism Drugs with Sanjeev Luther Rafael Pharmaceuticals
Learn MoreMarch 9, 2020 National Center for Biotechnology Information: The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells
Learn MoreMarch 7, 2020 OncLive: Dr. Mettu on the Potential of CPI-613 in Metastatic Pancreatic Cancer
Learn More - 2019
-
December 3, 2019 Targeted Oncology: Phase II Devimstat Study Expanded to Increase Access for Patients With Burkitts Lymphoma/Leukemia
Learn MoreNovember 10, 2019 Huffington Post: 13 Unexpected Reasons Why You Might Have A Fever
Learn MoreOctober 31, 2019 Clinical Leader: Rafael Pharmaceuticals Is Starving Cancer Cells
Learn MoreOctober 9, 2019 Targeted Oncology: New Phase III Trial Evaluates Devimistat Plus FOLFIRNOX in Metastatic Pancreatic Cancer
Learn MoreSeptember 5, 2019 Authority Magazine: 5 Things I Wish Someone Told Me Before I Became the CEO of Rafael Pharmaceuticals, With Sanjeev Luther
Learn MoreSeptember 4, 2019 MSN: 30 Things Oncologists Do to Prevent Cancer
Learn MoreAugust 1, 2019 Life Science Leader: Strategies For Success: Developing Drugs For Orphan Diseases
Learn MoreJuly 18, 2019 The Jerusalem Post: Breakthrough Pancreatic Cancer Treatment Phase III Trial opens in Israel
Learn MoreJuly 11, 2019 OncLive: Devimistat Could Have Practice-Changing Potential in Burkitt Lymphoma
Learn MoreJune 11, 2019 DDN News: Special Report on Cancer: Metabolic renaissance?
Learn MoreMay 29, 2019 U.S. News & World Report: Alex Trebek Says His Pancreatic Cancer Is ‘Near Remission’
Learn MoreMay 13, 2019 Winston Salem Journal: Dr. Zanetta Lamar: Cancer metabolism: Gaining momentum in the fight to stop cancer
Learn MoreMarch 29, 2019 Scientific American: A New Way to Fight Cancer
Learn MoreMarch 18, 2019 Investing News Network: Rafael Pharma Stands Out with Drugs Treating Difficult Cancers
Learn MoreMarch 12, 2019 CRAIN’S New York Business: NJ firm advancing drug for pancreatic, hard-to-treat cancers
Learn MoreMarch 7, 2019 OncLive: Dr. Mettu on the Potential of CPI-613® in Metastatic Pancreatic Cancer
Learn More - 2017
-
June 13, 2017 Drug Discovery News: Special Report on Cancer Metabolomics- Into the metabolic maelstrom
Learn MoreMarch 27, 2017 BioWorld: Next-generation oncology: New technologies and MOAs
Learn MoreMarch 24, 2017 BIOCENTURY: How Cornerstone’s CPI-613® leapfrogged to pivotal trials in AML and pancreatic cancer
Learn MoreMarch 23, 2017 MedCity News: Cornerstone gets green light for two pivotal cancer trials
Learn MoreMarch 17, 2017 PM 360 Movers and Shakers: Chi Van Dang, M.D., Ph.D., appointed to Cornerstone’s Board of Directors. Will also serve as Chair of its Scientific and Medical Advisory Boards
Learn MoreFebruary 14, 2017 WCTC-AM: Interview with Sanjeev Luther (COO, Cornerstone Pharmaceuticals)
Learn MoreFebruary 8, 2017 FirstWorld Pharma: Cornerstone Pharmaceuticals Announces the Addition of World-Renowned Experts to Scientific and Medical Advisory Boards
Learn MoreJanuary 30, 2017 BioWorld Appointments and Advancements:- Cornerstone’s new Board of Directors (Subscription Required)
Learn MoreJanuary 16, 2017 The Price of Business Radio: JP Morgan Biotech, Sanjeev Luther (COO, Cornerstone Pharmaceuticals) and Tim Pardee (Chief Oncologist, Cornerstone Pharmaceuticals) on CPI-613®
Learn MoreJanuary 14, 2017 Vital Options International: Dr Zanetta Lamar at ASH 2016- The data collected by Wake Forest Baptist Health
Learn MoreJanuary 14, 2017 Vital Options International: Dr Zanetta Lamar at ASH 2016- The cost of therapy and quality of care
Learn MoreJanuary 14, 2017 Vital Options International: Dr Timothy Pardee at ASH 2016- New Therapeutic Methods
Learn MoreJanuary 14, 2017 Vital Options International: Dr Timothy Pardee at ASH 2016- Addressing patients participating in clinical trials
Learn More - 2016
-
December 5, 2016 ecancer: Dr Timothy Pardee at ASH 2016 on TCA cycle inhibition by CPI-613® in older AML patients
Learn MoreDecember 5, 2016 ecancer: Dr Zanetta Lamar at ASH 2016 on dose escalation of CPI-613® with bendamustine for relapsed T Cell NHL
Learn More - 2015
-
January 9, 2015 OncLive: Dr. Powell at ASH 2014 on CPI-613®, Cytarabine, Mitoxantrone Combo for AML
Learn More - 2014
-
September 11, 2014 OncLive: Dr. Pardee on CPI-613®for Patients With R/R AML
Learn More - 2013
-
December 20, 2013 OncLive: Dr. Pardee Provides an Update on CPI-613® in advanced hematologic malignancies
Learn MoreNovember 1, 2013 Pharmaceutical Business Review: Cornerstone initiates Phase II trial of CPI-613® to treat metastatic pancreatic cancer patients
Learn MoreNovember 1, 2013 Drug Development Technology: Cornerstone begins Phase II study of pancreatic cancer drug
Learn MoreNovember 1, 2013 BioWorld Today: Clinic Roundup (subscription required)
Learn MoreOctober 28, 2013 Drug Development Technology: Cornerstone begins Phase II trial of lung cancer drug
Learn MoreOctober 17, 2013 BioPharma International: Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation
Learn MoreOctober 11, 2013 LymphomaInfo.net: Cornerstone Gets Orphan Drug Status For MDS Treatment
Learn MoreOctober 7, 2013 Medical News Today: Cornerstone Pharmaceuticals receives FDA orphan drug designation of CPI-613® for treatment of myelodysplastic syndrome
Learn MoreOctober 4, 2013 Hematology Times: Drug gets orphan designation for MDS (Registration Required)
Learn MoreOctober 3, 2013 Oncology Times: FDA Grants MDS Drug CPI-613® Orphan Drug Status
Learn MoreOctober 3, 2013 The MDS Beacon: Cornerstone Pharmaceuticals Receives FDA Orphan Drug Designation Of CPI-613® For Treatment Of Myelodysplastic Syndrome
Learn MoreJuly 25, 2013 OncLive: Dr. Powell Discusses the Next Steps for CPI-613®
Learn MoreJuly 10, 2013 OncLive: Dr. Pardee on CPI-613® in Hematologic Malignancies
Learn MoreJune 11, 2013 OncLive: Dr. Powell Discusses CPI-613® in Hematologic Malignancies
Learn More - 2011
-
December 14, 2011 Drug Discovery & Development: Cornerstone Releasing CPI-613® Data
Learn MoreDecember 13, 2011 BioWorld Today: ASH Roundup (subscription required)
Learn MoreDecember 6, 2011 Drug Discovery & Development: On Target Delivery
Learn MoreAugust 15, 2011 BioCentury: Powering down cancer
Learn MoreAugust 1, 2011 BioWorld Today: Bench Press (subscription required)
Learn More - 2010
-
November 29, 2010 The New York Times: Fuel lines of tumors are new target
Learn MoreSeptember 1, 2010 Start-Up Magazine: Profile on Cornerstone Pharmaceuticals
Learn MoreAugust 1, 2010 Drug Discovery News: Trends in cancer research
Learn MoreMay 1, 2010 Drug Discovery News: Cancer research turns a corner
Learn More